ATBPF Antibe Therapeutics Inc.

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CV:ATE.

$0.52    OTCQX
As of 01/25/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  10/09/2014
Outstanding shares:  51,872,661
Average volume:  33,076
Market cap:   $27,803,746
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   -1.00
PB ratio:   0.43
PS ratio:   3.10
Return on equity:   -38.61%
Net income %:   -244.31%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy